TY  - BOOK
AU  - Howard, Barbara V
AU  - Shara, Nawar M
AU  - Wang, Hong
TI  - Haptoglobin genotype is a consistent marker of  coronary heart disease risk among individuals with elevated  glycosylated hemoglobin
SN  - 0735-1097
PY  - 2013///
KW  - *Coronary Disease/ge [Genetics]
KW  - *Genotype
KW  - *Haptoglobins/ge [Genetics]
KW  - *Haptoglobins/me [Metabolism]
KW  - *Hemoglobin A, Glycosylated/ge [Genetics]
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Biological Markers/bl [Blood]
KW  - Case-Control Studies
KW  - Cohort Studies
KW  - Coronary Disease/bl [Blood]
KW  - Female
KW  - Glycosylation
KW  - Hemoglobin A, Glycosylated/me [Metabolism]
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Risk Factors
KW  - Up-Regulation/ge [Genetics]
KW  - Young Adult
KW  - MedStar Health Research Institute
KW  - Journal Article
KW  - Randomized Controlled Trial
KW  - Research Support, N.I.H., Extramural
KW  - Research Support, Non-U.S. Gov't
N1  - Available online from MWHC library: 1995 -  present, Available in print through MWHC library:1999-2007
N2  - BACKGROUND: Studies of the association between the  Hp polymorphism and CHD report inconsistent results.  Individuals with the Hp2-2 genotype produce Hp proteins with  an impaired ability to prevent oxidative injury caused by  elevated HbA(1c); CONCLUSIONS: Hp genotype was a significant  predictor of CHD among individuals with elevated HbA(1c).  Copyright  2013 American College of Cardiology Foundation.  Published by Elsevier Inc. All rights reserved; METHODS: HbA(1c) concentration and Hp genotype  were determined for 407 CHD cases matched 1:1 to controls  (from the NHS [Nurses' Health Study]) and in a replication  cohort of 2,070 individuals who served as the nontreatment  group in the ICARE (Prevention of Cardiovascular  Complications in Diabetic Patients With Vitamin E Treatment)  study, with 29 CHD events during follow-up. Multivariate  models were adjusted for lifestyle and CHD risk factors as  appropriate. A pooled analysis was conducted of NHS, ICARE,  and the 1 previously published analysis (a cardiovascular  disease case-control sample from the Strong Heart Study); OBJECTIVES: This study sought to investigate into  the biologically plausible interaction between the common  haptoglobin (Hp) polymorphism rs#72294371 and glycosylated  hemoglobin (HbA(1c)) on risk of coronary heart disease  (CHD); RESULTS: In the NHS, Hp2-2 genotype (39%  frequency) was strongly related to CHD risk only among  individuals with elevated HbA(1c) (>= 6.5%), an association  that was similar in the ICARE trial and the Strong Heart  Study. In a pooled analysis, participants with both the  Hp2-2 genotype and elevated HbA(1c) had a relative risk of  7.90 (95% confidence interval: 4.43 to 14.10) for CHD  compared with participants with both an Hp1 allele and  HbA(1c) <6.5% (p for interaction = 0.004), whereas the Hp2-2  genotype with HbA(1c) <6.5% was not associated with risk  (relative risk: 1.34 [95% confidence interval: 0.73 to  2.46])
UR  - http://dx.doi.org/10.1016/j.jacc.2012.09.063
ER  -